HPV-associated head and neck cancer: Unique features of epidemiology and clinical management

Annual Review of Medicine

Volumn 67, Issue , 2016, Pages 91-101

  Maxwell, Jessica H ^a   Grandis, Jennifer R ^b   Ferris, Robert L ^a,c  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Human papillomavirus; Oropharyngeal cancer; Oropharyngeal squamous cell carcinoma

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CARBOPLATIN; CISPLATIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DOCETAXEL; FLUOROURACIL; PACLITAXEL; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN E6; PROTEIN E7; PROTEIN P53; PROTEIN P63; RETINOBLASTOMA PROTEIN; STAT1 PROTEIN; TIPAPKINOGENE SOVACIVEC; TOLL LIKE RECEPTOR AGONIST; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 3; WART VIRUS VACCINE; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; DISTANT METASTASIS; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; HEAD AND NECK CANCER; HEAD AND NECK SURGERY; HIGH RISK PATIENT; HUMAN; IMMUNE SYSTEM; LASER SURGERY; LYMPH NODE METASTASIS; MALIGNANT TRANSFORMATION; MINIMALLY INVASIVE SURGERY; NECK DISSECTION; ONCOGENE; OROPHARYNX CANCER; OVERALL SURVIVAL; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; RISK ASSESSMENT; ROBOT ASSISTED SURGERY; SURGICAL APPROACH; SURVIVAL RATE; T LYMPHOCYTE; TONSIL CANCER; TRANSORAL ROBOTIC SURGERY; TUMOR ASSOCIATED LEUKOCYTE; VIRUS CARCINOGENESIS; WART VIRUS; CARCINOMA, SQUAMOUS CELL; CELL TRANSFORMATION; COMPLICATION; IMMUNE EVASION; IMMUNOLOGY; MULTIMODALITY CANCER THERAPY; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRIDAE; PATHOLOGY; PROGNOSIS; RADIATION DOSE FRACTIONATION; RISK FACTOR; VIROLOGY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CELL TRANSFORMATION, NEOPLASTIC; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; HUMANS; IMMUNE EVASION; MINIMALLY INVASIVE SURGICAL PROCEDURES; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PROGNOSIS; RISK FACTORS;

EID: 84954532413     PISSN: 00664219     EISSN: 1545326X     Source Type: Book Series    
DOI: 10.1146/annurev-med-051914-021907     Document Type: Article

References (57)

1. Bodily J, Laimins LA. (2011). Persistence of human papillomavirus infection: keys tomalignant progression. Trends Microbiol. 19: 33-39
2. Munoz N, Bosch FX, de Sanjose S, et al. (2003). Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 348: 518-27
3. Gillison ML, Koch WM, Capone RB, et al. (2000). Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J. Natl. Cancer Inst. 92: 709-20
4. Maxwell JH, Kumar B, Feng FY, et al. (2010). HPV-positive/p16-positive/EBV-negative nasopharyngeal carcinoma in white North Americans. Head Neck 32: 562-67
5. Ryerson AB, Peters ES, Coughlin SS, et al. (2008). Burden of potentially human papillomavirus-Associated cancers of the oropharynx and oral cavity in the US, 1998-2003. Cancer 113: 2901-9
6. Conway DI, Brenner DR, McMahon AD, et al. (2015). Estimating and explaining the effect of education and income on head and neck cancer risk: INHANCE consortium pooled analysis of 31 case-control studies from 27 countries. Int. J. Cancer 136: 1125-39
7. Chaturvedi AK, Engels EA, Pfeiffer RM, et al. (2011). Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J. Clin. Oncol. 29: 4294-301
8. Chenevert J, Chiosea S. (2012). Incidence of human papillomavirus in oropharyngeal squamous cell carcinomas: now and 50 years ago. Hum. Pathol. 43: 17-22
9. Maxwell JH, Ferris RL, Gooding W, et al. (2013). Extracapsular spread in head and neck carcinoma: impact of site and human papillomavirus status. Cancer 119: 3302-8
10. Ang KK, Harris J, Wheeler R, et al. (2010). Human papillomavirus and survival of patients with oropharyngeal cancer. N. Engl. J. Med. 363: 24-35
11. Fakhry C, Westra WH, Li S, et al. (2008). Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J. Natl. Cancer Inst. 100: 261-69
12. D'Souza G, Kreimer AR, Viscidi R, et al. (2007). Case-control study of human papillomavirus and oropharyngeal cancer. N. Engl. J. Med. 356: 1944-56
13. Bajos N, Bozon M, Beltzer N, et al. (2010). Changes in sexual behaviours: from secular trends to public health policies. AIDS 24: 1185-91
14. Turner CF, Danella RD, Rogers SM. (1995). Sexual behavior in the United States 1930-1990: trends and methodological problems. Sex. Transm. Dis. 22: 173-90
15. D'Souza G, Cullen K, Bowie J, et al. (2014). Differences in oral sexual behaviors by gender, age, and race explain observed differences in prevalence of oral human papillomavirus infection. PLoS ONE 9: e86023
16. Thorland EC, Myers SL, Gostout BS, Smith DI. (2003). Common fragile sites are preferential targets for HPV16 integrations in cervical tumors. Oncogene 22: 1225-37
17. O'Brien PM, Saveria Campo M. (2002). Evasion of host immunity directed by papillomavirus-encoded proteins. Virus Res. 88: 103-17
18. Stanley MA, Pett MR, Coleman N. (2007). HPV: from infection to cancer. Biochem. Soc. Trans. 35: 1456-60
19. Kanodia S, Fahey LM, Kast WM. (2007). Mechanisms used by human papillomaviruses to escape the host immune response. Curr. Cancer Drug Targets 7: 79-89
20. Scott M, Nakagawa M, Moscicki AB. (2001). Cell-mediated immune response to human papillomavirus infection. Clin. Diagn. Lab. Immunol. 8: 209-20
21. Beachler DC, Viscidi R, Sugar EA, et al. (2015). A longitudinal study of human papillomavirus 16 L1, E6, and E7 seropositivity and oral human papillomavirus 16 infection. Sex. Transm. Dis. 42: 93-97
22. Gillison ML, Broutian T, Pickard RK, et al. (2012). Prevalence of oral HPV infection in the United States, 2009-2010. JAMA 307: 693-703
23. Ragin CC, Taioli E. (2007). Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: review and meta-Analysis. Int. J. Cancer 121: 1813-20
24. Parsons JT, Mendenhall WM, Stringer SP, et al. (2002). Squamous cell carcinoma of the oropharynx: surgery, radiation therapy, or both. Cancer 94: 2967-80
25. Bourhis J, Overgaard J, Audry H, et al. (2006). Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-Analysis. Lancet 368: 843-54
26. Forastiere AA, Zhang Q, Weber RS, et al. (2013). Long-Term results ofRTOG91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J. Clin. Oncol. 31: 845-52
27. Calais G, Alfonsi M, Bardet E, et al. (1999). Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J. Natl. Cancer Inst. 91: 2081-86
28. Fischer CA, Zlobec I, Green E, et al. (2010). Is the improved prognosis of p16 positive oropharyngeal squamous cell carcinoma dependent of [sic] the treatment modality? Int. J. Cancer 126: 1256-62
29. Straetmans JM, Olthof N, Mooren JJ, et al. (2009). Human papillomavirus reduces the prognostic value of nodal involvement in tonsillar squamous cell carcinomas. Laryngoscope 119: 1951-57
30. Ward MJ, Mellows T, Harris S, et al. (2015). Staging and treatment of oropharyngeal cancer in the human papillomavirus era. Head Neck 37: 1002-13
31. Spector ME, Gallagher KK, Bellile E, et al. (2014). Patterns of nodal metastasis and prognosis in human papillomavirus-positive oropharyngeal squamous cell carcinoma. Head Neck 36: 1233-40
32. Strong MS, Jako GJ. (1972). Laser surgery in the larynx. Early clinical experience with continuous CO2 laser. Ann. Otol. Rhinol. Laryngol. 81: 791-98
33. Haughey BH, Hinni ML, Salassa JR, et al. (2011). Transoral laser microsurgery as primary treatment for advanced-stage oropharyngeal cancer: a United States multicenter study. Head Neck 33: 1683-94
34. Grant DG, Hinni ML, Salassa JR, et al. (2009). Oropharyngeal cancer: a case for single modality treatment with transoral laser microsurgery. Otolaryngol.-Head Neck Surg. 135: 1225-30
35. Huang K, Xia P, Chuang C, et al. (2008). Intensity-modulated chemoradiation for treatment of stage III and IV oropharyngeal carcinoma: the University of California-San Francisco experience. Cancer 113: 497-507
36. O'Malley BWJr, Weinstein GS, Snyder W, Hockstein NG. (2006). Transoral robotic surgery (TORS) for base of tongue neoplasms. Laryngoscope 116: 1465-72
37. Weinstein GS, O'Malley BW Jr, Cohen MA, Quon H. (2010). Transoral robotic surgery for advanced oropharyngeal carcinoma. Otolaryngol.-Head Neck Surg. 136: 1079-85
38. Genden EM, Desai S, Sung CK. (2009). Transoral robotic surgery for the management of head and neck cancer: a preliminary experience. Head Neck 31: 283-89
39. Hurtuk A, Agrawal A, Old M, et al. (2011). Outcomes of transoral robotic surgery: a preliminary clinical experience. Otolaryngol.-Head Neck Surg. 145: 248-53
40. Maxwell JH, Mehta V, Wang H, et al. (2014). Quality of life in head and neck cancer patients: impact of HPV and primary treatment modality. Laryngoscope 124: 1592-97
41. Maxwell JH, Kumar B, Feng FY, et al. (2010). Tobacco use in human papillomavirus-positive advanced oropharynx cancer patients related to increased risk of distant metastases and tumor recurrence. Clin. Cancer Res. 16: 1226-35
42. Holliday MA, Tavaluc R, Zhuang T, et al. (2013). Oncologic benefit of tonsillectomy in stage I and II tonsil cancer: a surveillance epidemiology and end results database review. Otolaryngol.-Head Neck Surg. 139: 362-66
43. O'Sullivan B, Huang SH, Siu LL, et al. (2013). Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis. J. Clin. Oncol. 31: 543-50
44. Schiller JT, Castellsague X, Garland SM. (2012). A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 30(Suppl. 5): F123-38
45. Gildener-Leapman N, Lee J, Ferris RL. (2014). Tailored immunotherapy for HPV positive head and neck squamous cell cancer. Oral Oncol. 50: 780-84
46. Gildener-Leapman N, Ferris RL, Bauman JE. (2013). Promising systemic immunotherapies in head and neck squamous cell carcinoma. Oral Oncol. 49: 1089-96
47. Brun JL, Dalstein V, Leveque J, et al. (2011). Regression of high-grade cervical intraepithelial neoplasia with TG4001 targeted immunotherapy. Am. J. Obstet. Gynecol. 204: 169.e1-169.e8
48. Sewell DA, Pan ZK, Paterson Y. (2008). Listeria-based HPV-16 E7 vaccines limit autochthonous tumor growth in a transgenic mouse model for HPV-16 transformed tumors. Vaccine 26: 5315-20
49. Quezada S, Peggs K. (2013). Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer. Br. J. Cancer 108: 1560-65
50. Lyford-Pike S, Peng S, Young G, et al. (2013). Evidence for a role of the PD-1: PD-L1 pathway in immune resistance of HPV-Associated head and neck squamous cell carcinoma. Cancer Res. 73: 1733-41
51. Badoual C, Hans S, Merillon N, et al. (2013). PD-1-expressing tumor infiltrating T cells are a favorable prognostic biomarker in HPV-Associated head and neck cancer. Cancer Res. 73: 128-38
52. Cancer Genome Atlas Network. (2015). Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 517: 576-82
53. Seiwert TY, Zuo Z, Keck MK, et al. (2015). Integrative and comparative genomic analysis ofHPV-positive and HPV-negative head and neck squamous cell carcinomas. Clin. Cancer Res. 21: 632-41
54. Parfenov M, Pedamallu CS, Gehlenborg N, et al. (2014). Characterization of HPV and host genome interactions in primary head and neck cancers. PNAS 111: 15544-49
55. Akagi K, Li J, Broutian TR, et al. (2014). Genome-wide analysis of HPV integration in human cancers reveals recurrent, focal genomic instability. Genome Res. 24: 185-99
56. Ojesina AI, Lichtenstein L, Freeman SS, et al. (2014). Landscape of genomic alterations in cervical carcinomas. Nature 506: 371-75
57. Rusan M, Li YY, Hammerman PS. (2015). Genomic landscape of human papillomavirus-Associated cancers. Clin. Cancer Res. 21: 2009-19